Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.

From CN-Bio 1 Dec 2021

$Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients$

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients.

29 Nov 2021

TXA drug has minimal impact in controlling blood loss in severely injured trauma patients

A recent study found that the drug tranexamic acid has minimal impact in controlling blood loss in severely injured trauma patients at the standard doses given, according to researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

REGEN-COV is effective in preventing severe COVID-19 in immunocompromised individuals

A recent study assesses the efficacy of repeat doses of REGEN-COV in SARS-CoV-2-negative adults who were healthy or had chronic medical conditions.

18 Nov 2021

Model simulations show no need for DEX dose adjustments in COVID-19 patients with liver disease

A recent study sed PBPK modeling to demonstrate the use of DEX PKs for the treatment of COVID-19 in patients with liver impairment.

17 Nov 2021

Promising results from Phase II REGEN-COV study

Initial results of the REGEN-COV Phase II study are presented.

15 Nov 2021

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

BioIVT to highlight the use of SCHH model to investigate drug-drug interaction of bempedoic acid

BioIVT, a leading provider of research models and services for drug and diagnostic development, is hosting a webinar in which researchers will discuss how they used a sandwich-cultured human hepatocyte (SCHH) model to investigate the drug-drug interaction (DDI) potential of bempedoic acid, a drug that was recently approved to treat hypercholesterolemia.

9 Nov 2021

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

GammaDelta Therapeutics initiates first-in-human phase 1 trial of GDX012 for the treatment of acute myeloid leukemia

GammaDelta Therapeutics Ltd., a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukemia.

17 Sep 2021

Results from Phase 0/1 trial of ribociclib plus everolimus in patients with high-grade glioma announced

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).

13 Sep 2021

Discovery of new urinary biomarkers can boost the surveillance of synthetic drug abuse

A team of researchers from the National University of Singapore has come up with a new solution to boost the surveillance of designer drug abuse.

30 Aug 2021

Aston University secures KTP project to assist Catalent in developing orally disintegrating tablets

Aston University researchers based in the College of Health and Life Sciences have been awarded a Knowledge Transfer Partnership (KTP) project by Innovate UK, to bring its academic and scientific expertise to assist Catalent in the development of its Zydis® technology, the leading orally disintegrating tablet (ODT).

27 Aug 2021

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Removal of race from kidney function estimates may negatively impact care for Black cancer patients

An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.

14 Aug 2021

Innovative therapeutic platform for blood-to-brain delivery of antisense oligonucleotide therapy

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

12 Aug 2021

Nanotechnology may help improve treatment for colorectal cancer and melanoma

University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.